MX2016014875A - Immunogenic giant extracellular vesicles (vegs) of parasitic protozoa and methods for their induction and purification. - Google Patents
Immunogenic giant extracellular vesicles (vegs) of parasitic protozoa and methods for their induction and purification.Info
- Publication number
- MX2016014875A MX2016014875A MX2016014875A MX2016014875A MX2016014875A MX 2016014875 A MX2016014875 A MX 2016014875A MX 2016014875 A MX2016014875 A MX 2016014875A MX 2016014875 A MX2016014875 A MX 2016014875A MX 2016014875 A MX2016014875 A MX 2016014875A
- Authority
- MX
- Mexico
- Prior art keywords
- vesicles
- vegs
- induction
- purification
- methods
- Prior art date
Links
- 230000003071 parasitic effect Effects 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000000746 purification Methods 0.000 title abstract 2
- 241000224432 Entamoeba histolytica Species 0.000 abstract 3
- 229940007078 entamoeba histolytica Drugs 0.000 abstract 2
- 208000006503 Amebic Liver Abscess Diseases 0.000 abstract 1
- 241000224467 Giardia intestinalis Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241000223109 Trypanosoma cruzi Species 0.000 abstract 1
- 229940085435 giardia lamblia Drugs 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 210000003812 trophozoite Anatomy 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/10—Protozoa; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to giant secreted (extracellular) vesicles (referred to as VEGs) that are associated with parasitic protozoan species, which have dimensions of 500-400 nm in diameter, and to methods to allow their induction, secretion and purification. These vesicles possess proteolytic activity and are composed of a large amount of proteins; in particular, they were obtained from Entamoeba histolytica trophozoites (referred to as EhVEG) and from other parasitic protozoa, such as Giardia lamblia and Trypanosoma cruzi. The invention also relates to the use of such vesicles, for example EhVEGs, to immunize mammals susceptible to infection by Entamoeba histolytica. The present invention also describes effective vaccine immunogenic pharmaceutical compositions comprising the induced and isolated VEGs, for example EhVEGs, which are useful for the treatment and prevention of amebic hepatic abscess. The present invention represents the first report that demonstrates and/or verifies that E. histolytica secretes extracellular vesicles of large dimensions into the culture medium.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2016014875A MX2016014875A (en) | 2016-11-11 | 2016-11-11 | Immunogenic giant extracellular vesicles (vegs) of parasitic protozoa and methods for their induction and purification. |
| PCT/IB2017/056917 WO2018087644A2 (en) | 2016-11-11 | 2017-11-06 | Immunogenic giant extracellular vesicles (vegs) of parasitic protozoa and methods for their induction and purification |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2016014875A MX2016014875A (en) | 2016-11-11 | 2016-11-11 | Immunogenic giant extracellular vesicles (vegs) of parasitic protozoa and methods for their induction and purification. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016014875A true MX2016014875A (en) | 2018-05-10 |
Family
ID=62109610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014875A MX2016014875A (en) | 2016-11-11 | 2016-11-11 | Immunogenic giant extracellular vesicles (vegs) of parasitic protozoa and methods for their induction and purification. |
Country Status (2)
| Country | Link |
|---|---|
| MX (1) | MX2016014875A (en) |
| WO (1) | WO2018087644A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024033684A1 (en) * | 2022-08-09 | 2024-02-15 | Universidade De Coimbra | Compositions, methods and uses of extracellular vesicles of giardia spp |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1498144A1 (en) * | 2003-07-15 | 2005-01-19 | Universite Pierre Et Marie Curie Paris Vi | Extracellular vesicles from non-pathogenic amoebae useful as vehicle for transferring a molecule of interest to an eukaryotic cell |
-
2016
- 2016-11-11 MX MX2016014875A patent/MX2016014875A/en unknown
-
2017
- 2017-11-06 WO PCT/IB2017/056917 patent/WO2018087644A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018087644A3 (en) | 2018-07-12 |
| WO2018087644A2 (en) | 2018-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024015440A (en) | ANTI-PHF-TAU ANTIBODIES AND THEIR USES | |
| EA201990019A1 (en) | COMPOUNDS AND COMPOSITIONS FOR SUSPENSION OF SHP2 ACTIVITY | |
| WO2016024205A8 (en) | Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene | |
| EA201890162A1 (en) | ANTIBODIES TO CD40 WITH ENHANCED AGONISTIC ACTIVITY | |
| GEP20217328B (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| EA201890175A1 (en) | ANTIBODIES TO CD40 | |
| TN2013000467A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| WO2016127179A3 (en) | Immunomodulatory agents | |
| EA201692031A1 (en) | PHARMACEUTICAL COMPOSITION WITH ACTIVE ACTION WITH RESPECT TO CHRONIC BACTERIAL INFECTIONS | |
| EA201891925A1 (en) | ANTIBODIES TO CD40 WITH STRENGTHENED AGONISTIC ACTIVITY | |
| JOP20220119A1 (en) | TREM2 antibodies and their uses | |
| HK1255331A1 (en) | Anti-pcsk9 antibodies and uses thereof | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| EA201991041A1 (en) | VACCINE AGAINST PORK PARVOVIRUS AND PIG REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND METHODS FOR ITS PRODUCTION | |
| EA201691521A1 (en) | ANTIBODIES TO INTERLEUKIN-21 | |
| EP3630102A4 (en) | FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER | |
| WO2015127140A3 (en) | Marburg monoclonal antibodies | |
| CR20200027A (en) | AGENTS, USES AND METHODS FOR TREATMENT | |
| EA201990010A1 (en) | INFECTIOUS Bronchitis Virus Vaccine | |
| EA201990988A1 (en) | ANTIBODIES AGAINST CHIKV AND WAYS OF THEIR APPLICATION | |
| EA201990222A1 (en) | ANTIBODIES TO O2 AND WAYS OF THEIR APPLICATION | |
| MA42640A1 (en) | Dmdv and e2 fusion proteins and their uses | |
| EA202190807A1 (en) | ANTIBODIES TO SYNUCLEINE | |
| EA202191145A1 (en) | VACCINE VIB 4/91 WITH HETEROLOGICAL SPINE PROTEIN | |
| WO2018088850A3 (en) | Antibody binding specifically to cd40 and use thereof |